Literature DB >> 1497489

Cytotoxicity of mebendazole against established cell lines from the human, rat, and mouse liver.

F Higa1, K Kitsukawa, M Gaja, M Tateyama, K Shikiya, Y Shigeno, F Kinjo, A Saito.   

Abstract

The direct cytotoxicity of mebendazole (MBZ) was investigated by using cell lines derived from human, mouse and rat liver. It was demonstrated that Chang liver cells (derived from human liver) were more sensitive to the cytotoxic effects of MBZ than the other two cell lines. Longer incubation of the cells with MBZ resulted in stronger toxicity, and the cytotoxicity was dependent on the MBZ concentration above a certain threshold value (0.25-0.50 mg/l in a 42-h culture). Inhibition of the proliferation of Chang liver cells by MBZ was detected at a concentration of 0.008 mg/l, a lower concentration than that having a cytotoxic effect. The other two cell lines were less sensitive to the inhibitory effect of MBZ. Proliferation of human mononuclear cells following stimulation by phytohemagglutinin (PHA) was inhibited by MBZ, and this inhibition was more extensive than that of cells stimulated with whole formalin-treated Pseudomonas aeruginosa. It is suggested that dividing cells may be more sensitive to MBZ cytotoxicity. This anti-proliferative effect may be related to its clinically known side effects, such as hepatotoxicity and bone marrow suppression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497489     DOI: 10.1007/bf01974020

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  19 in total

1.  Treatment of strongyloidiasis with mebendazole.

Authors:  S Mravak; W Schopp; U Bienzle
Journal:  Acta Trop       Date:  1983-03       Impact factor: 3.112

2.  Complication of mebendazole treatment for hydatid disease.

Authors:  I M Murray-Lyon; K W Reynolds
Journal:  Br Med J       Date:  1979-11-03

Review 3.  Mebendazole and related anthelmintics.

Authors:  H Van den Bossche; F Rochette; C Hörig
Journal:  Adv Pharmacol Chemother       Date:  1982

4.  Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis.

Authors:  A Davis; Z S Pawlowski; H Dixon
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

5.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  [Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis].

Authors:  R Seitz; W Schwerk; R Arnold
Journal:  Z Gastroenterol       Date:  1983-07       Impact factor: 2.000

7.  Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease.

Authors:  P A Braithwaite; M S Roberts; R J Allan; T R Watson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  [Treatment of strongyloidiasis with mebendazole and its combination with thiabendazole].

Authors:  K Shikiya; T Kuniyoshi; A Higashionna; T Arakkaki; T Oyakawa; K Kadena; F Kinjo; A Saito; R Asato
Journal:  Kansenshogaku Zasshi       Date:  1990-11

9.  Evaluation of a new antihelminthic for trichuriasis, hookworm, and stronglyloidiasis.

Authors:  I A Musgrave; R B Hawes; J L Jameson; R A Sloane; P A Quayle
Journal:  Med J Aust       Date:  1979-05-05       Impact factor: 7.738

10.  Effect of plasma mebendazole concentrations in the treatment of human echinococcosis.

Authors:  W Woodtli; J Bircher; F Witassek; J Eckert; B Wüthrich; R W Ammann
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.